Skip to content

Study on treatment strategy of refractory gastroesophageal reflux induced cough

Study on treatment strategy of refractory gastroesophageal reflux induced cough

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-13003066
Enrollment
Unknown
Registered
2013-02-22
Start date
2013-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal reflux induced cough (GERC)

Interventions

One cohort:Omeprazole, domperidone, ranitidine.

Sponsors

Shanghai Tongji Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Chronic cough with or without the typical upper gastrointestinal symptoms such as regurgitation, heartburn and chest pain; 2) multi-channel intraluminal impedance combined with pH monitoring (MII-pH) confirmed abnormal acid or non-acid reflux, as shown by DeMeester score of >=14.72 and/or syndrome association probability (SAP) for acid or non-acid reflux of >=95%; 3) cough fails to improve with 2 months of standard anti-reflux treatment consisting of omeprazole 20 mg, twice daily, plus domperidone 10 mg, three times a day, but disappears or improves with the consequent intensified anti-reflux regimen.

Exclusion criteria

Exclusion criteria: The other cause of chronic cough such as upper airway cough syndrome, cough variant asthma and eosinophilic bronchitis are excluded.

Design outcomes

Primary

MeasureTime frame
cough symptom score;reflux symptom score;

Countries

China

Contacts

Public ContactZhongmin Qiu
qiuzhongmin@yahoo.com.hk+86 021 66111286

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 4, 2026